Everest Medicines (HKSE:01952) Gross-Profit-to-Asset % : 11.62% (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Everest Medicines Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Everest Medicines's annualized Gross Profit for the quarter that ended in Dec. 2024 was HK$631.6 Mil. Everest Medicines's average Total Assets over the quarter that ended in Dec. 2024 was HK$5,434.0 Mil. Therefore, Everest Medicines's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 was 11.62%.

Everest Medicines Gross-Profit-to-Asset % Historical Data

The historical data trend for Everest Medicines's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Everest Medicines Gross-Profit-to-Asset % Chart

Everest Medicines Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

0.12

1.46

9.69

Everest Medicines Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial							0.23	0.18	2.95	8.37	11.62

Competitive Comparison of Everest Medicines's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Everest Medicines's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Everest Medicines's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Everest Medicines's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Everest Medicines's Gross-Profit-to-Asset % falls into.

Save Embed

;

Save Embed

;

Everest Medicines Gross-Profit-to-Asset % Calculation

Everest Medicines's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2024 )	/	( (Total Assets (A: Dec. 2023 )	+	Total Assets (A: Dec. 2024 ))	/ count )
	=	562.539	/	( (6314.136	+	5294.423)	/ 2 )
	=	562.539	/	5804.2795
	=	9.69 %

Everest Medicines's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Dec. 2024 ))	/ count )
	=	631.646	/	( (5573.648	+	5294.423)	/ 2 )
	=	631.646	/	5434.0355
	=	11.62 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Everest Medicines Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Everest Medicines's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Everest Medicines Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Everest Medicines Ltd (HKSE:01952) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

6HN:Germany

Address

1168 West Nanjing Road, 16th Floor, CITIC Pacific Plaza, Jing’an District, Shanghai, CHN, 200041

Website

https://www.everestmedicines.com

Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes; Nefecon (TarpeyoTM), EVER001 (previously known as XNW1011), PTX-COVID19-B, Eravacycline (Xerava), EVER206 (also known as SPR206), and others.

Executives

Fu Wei	2307 Founder of a discretionary trust who can infl
Nova Aqua Limited	2201 Interest of corporation controlled by you
C-bridge Capital Gp Iv, Ltd.	2201 Interest of corporation controlled by you
C-bridge Healthcare Fund Gp Iv, L.p.	2201 Interest of corporation controlled by you
C-bridge Healthcare Fund Iv, L.p.	2201 Interest of corporation controlled by you
Tf Capital Iv Ltd.	2201 Interest of corporation controlled by you
C-bridge Capital Gp, Ltd.	2501 Other
C-bridge Healthcare Fund Gp Ii, L.p.	2501 Other
C-bridge Healthcare Fund Ii, L.p.	2501 Other
C-bridge Investment Everest Limited	2501 Other
Tf Capital Ii Ltd.	2501 Other
Everest Management Holding Co., Ltd.	2101 Beneficial owner
Fu Wei	2307 Founder of a discretionary trust who can infl
C-bridge Joint Value Creation Limited	2201 Interest of corporation controlled by you
Kolchinsky Anna Inge Leonore Haas	2202 Interest of your spouse

Everest Medicines Headlines

No Headlines